Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Trial details
- Registry ID
- NCT07563881
- Drugs studied
- RAP-219
TrialRedline tracks 5 clinical trials sponsored by Rapport Therapeutics Inc.: 2 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1NCT07563881 | RAP-219 | Recruiting | 2029-07Estimated |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-2NCT07594119 | RAP-219 | Recruiting | 2029-07Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresNCT07219407 | RAP-219 | Recruiting | 2028-02-03Estimated |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderNCT07046494 | RAP-219 | Completed | 2026-08-05Actual |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyNCT06377930 | RAP-219 | Completed | 2025-09-26Actual |
Names as written in the registry records.
NCT07046494 · Rapport Therapeutics Inc.
Before: Active not recruiting. After: Completed.
NCT07046494 · Rapport Therapeutics Inc.
Before: Estimated. After: Actual.
Before: 250 participants (planned). After: 253 participants (actual).
Before: Estimated. After: Actual.
Before: Sep 2026. After: 5 Aug 2026.
Before: Recruiting. After: Active not recruiting.
NCT07594119 · Rapport Therapeutics Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07563881 · Rapport Therapeutics Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07046494 · Rapport Therapeutics Inc.
Before: 224 participants (planned). After: 250 participants (planned).
Before: Oct 2026. After: Sep 2026.
NCT06377930 · Rapport Therapeutics Inc.
Before: Estimated. After: Actual.
Before: 28 Jul 2025. After: 26 Sep 2025.
Before: Active not recruiting. After: Completed.
NCT07219407 · Rapport Therapeutics Inc.
Before: Not yet recruiting. After: Recruiting.